Clinical Trial

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-15.
Status change: Recruiting → Enrolling by Invitation 2024-08-08
Trial Details
NCT Number NCT06186804
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions cGvHD
Enrollment 64 participants
Start Date 2023-05-30
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-12